Wednesday, December 7, 2016

REPORT: The 8 biggest challenges facing clinical trial professionals (pt. 2)


Over the last year, we interviewed dozens of clinical trial professionals representing pharma, CROs, sites and vendors. We asked them all about the biggest challenges they are facing and eight answers came up time and time again. Here we reveal the most common after the top four (which we explored here).

Staff Roles & Responsibilities (9%)

As the complexity and rate of change in trials both continue to increase, hiring and training the right staff is getting equally tricky. Respondents commented that ‘working in a constantly dynamic environment both in and out of the company’ means that ‘roles and responsibilities are evolving’.
Another aspect is the ‘increasingly remote nature of teams’ which has ‘an impact on how we manage and retain staff’. Similarly, with trials becoming more and more geographically diverse, another new challenge is ‘obtaining experienced clinical research professionals in developing countries’.

Technology (9%)

Technology is already playing a massive role in improving many aspects of trials and is rightly seen as one of the great hopes for future. However, with it, there are a whole raft of new challenges facing those running, participating in and regulating trials. As one respondent put it: ‘With technology, so much is happening so fast, the challenge is how to select and use the RIGHT technology, and for that technology to gain the acceptance of patients, healthcare professionals and regulators.’

Governance and oversight (9%)

Strategic partnerships, vendors, study sites, CROs; partnerships are playing a more important role in almost every aspect of trials today and the management of them can often prove challenging.
From the perspective of a study site, one particular challenge is the ‘involvement of a huge number of vendors in the studies’.

New drugs (5%)

Brand new classes of drug require different ways of running trials. Cell therapies, genomics, personalised treatments and whatever ‘the next big breakthrough is’ were all mentioned by the respondents as creating new issues in ‘demonstrating clinical effectiveness’.

No comments: